SESN - Sesen Bio, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.0700
+0.0450 (+4.39%)
At close: 4:00PM EDT

1.1000 +0.03 (2.80%)
After hours: 5:29PM EDT

Stock chart is not supported by your current browser
Previous Close1.0250
Open1.0500
Bid1.0700 x 3200
Ask1.0700 x 1300
Day's Range1.0301 - 1.0950
52 Week Range0.6610 - 3.5000
Volume1,141,971
Avg. Volume1,517,200
Market Cap82.878M
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.5500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • ACCESSWIRE26 days ago

    Four Healthcare Stocks Getting a Boost on Thursday

    CORAL GABLES, FL / ACCESSWIRE / March 28, 2019 / The healthcare stock market has been a hotbed of excitement in the first few months of 2019 as companies in the industry have focused their efforts on developing innovative technologies and treatments for consumers. Consumers depend and expect healthcare companies to invest in new forms of drug treatments and other aspects of the care experience so that, when a patient needs care, they don't have to look very far. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Arcturus Therapeutics Ltd (ARCT), Sesen Bio Inc (SESN), and Regulus Therapeutics Inc (RGLS) are 4 healthcare companies making moves on Thursday.

  • GlobeNewswire27 days ago

    Positive Results and New Technology Give Rise to Antibody Dominance

    POINT ROBERTS, Wash. and DELTA, British Columbia, March 27, 2019 -- Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of SESN earnings conference call or presentation 4-Mar-19 1:00pm GMT

    Q4 2018 Sesen Bio Inc Earnings Call

  • What Kind Of Shareholder Owns Most Sesen Bio, Inc. (NASDAQ:SESN) Stock?
    Simply Wall St.2 months ago

    What Kind Of Shareholder Owns Most Sesen Bio, Inc. (NASDAQ:SESN) Stock?

    Every investor in Sesen Bio, Inc. (NASDAQ:SESN) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insidersRead More...

  • Business Wire2 months ago

    Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial

    Company Announces Additional Key Primary and Secondary Endpoints Further Supporting Vicinium® Treatment Potential in High-Risk Non-Muscle Invasive Bladder Cancer

  • Business Wire2 months ago

    Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial

    Sesen Bio , a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that Company management will host a conference call and webcast on Monday, March 4, 2019 at 8:00 a.m.

  • ACCESSWIRE3 months ago

    Health Stocks Benefitting the Most from Rally

    HENDERSON, NV / ACCESSWIRE / January 22, 2019 / The stock market reached a level toward the end of last year where investors and analysts feared a recession. Some of this fear was over a U.S. China trade ...

  • Sesen Bio, Inc. (NASDAQ:SESN): A Fundamentally Attractive Investment
    Simply Wall St.3 months ago

    Sesen Bio, Inc. (NASDAQ:SESN): A Fundamentally Attractive Investment

    Sesen Bio, Inc. (NASDAQ:SESN) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case of Read More...

  • Business Wire4 months ago

    Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer

    Complete Response Rates from All Four Time Points in Carcinoma in Situ Patients In-line with Phase 2 Data

  • ACCESSWIRE4 months ago

    4 Healthcare Stocks That Could Test December Highs

    CORAL GABLES, FL/ ACCESSWIRE / December 27,2018 / As the new year is rapidly approaching, companies in the healthcare sector are working tirelessly to create and implement nuanced methods for treating patients with a myriad of diseases and ailments. From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Allscripts Healthcare Solutions Inc (MDRX), ZIOPHARM Oncology Inc (ZIOP), and Sesen Bio Inc (SESN) are 4 healthcare stocks worth paying attention to before the end of the year. Premier Health Group (PHGRF) (PHGI), a company dominating the telehealth sector of the healthcare industry, has enjoyed a strong month of bullish trading, with Company shares soaring well above the 30% mark in a 30-day period.

  • Business Wire4 months ago

    Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer

    Sesen Bio, Inc. (SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that company management will host a conference call on Thursday, Jan. 3, 2018 at 8:30 a.m. ET to review updated data from its Phase 3 VISTA Trial of Vicinium™ for the treatment of patients with high-grade non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin. The webcast can be accessed in the Investor Relations section of the company's website at www.sesenbio.com. The replay of the webcast will be available in the investor section of the company’s website at www.sesenbio.com for 60 days following the call.

  • Business Wire5 months ago

    Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer

    Sesen Bio, Inc. (SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced the appointment of Dennis Kim, M.D., MPH, as chief medical officer. In this role, Dr. Kim will oversee the continued Phase 3 development of Vicinium, Sesen Bio’s lead targeted fusion protein, for patients with high-grade non-muscle invasive bladder cancer (NMIBC), as well as preparations for a marketing authorization submission and pre-commercial activities. “We are thrilled to welcome Dennis to the Sesen Bio team and look forward to leveraging his deep drug development experience, particularly as we approach both six and 12-month data readouts from our VISTA Trial of Vicinium,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

  • ACCESSWIRE5 months ago

    3 Health Care Stocks Seeing Heightened Activity After Midterms

    Sesen Bio, Inc. (SESN) saw a stronger premarket session on Thursday morning. "2018 has been a year of focused execution for Sesen Bio, led by the advancement of the Phase 3 program for Vicinium for patients with NMIBC," said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

  • Business Wire5 months ago

    Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts

    Company Expects to Report Six-Month Update from VISTA Trial in December 2018; On-Track to Report 12-Month VISTA Trial Data in Mid-2019

  • Implied Volatility Surging for Sesen Bio (SESN) Stock Options
    Zacks6 months ago

    Implied Volatility Surging for Sesen Bio (SESN) Stock Options

    Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

  • Simply Wall St.7 months ago

    Do Institutions Own Shares In Sesen Bio Inc (NASDAQ:SESN)?

    Every investor in Sesen Bio Inc (NASDAQ:SESN) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • Business Wire7 months ago

    Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018

    Sesen Bio, Inc. (SESN), a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018. The ongoing VISTA registration trial is evaluating Vicinium™, Sesen Bio’s lead product candidate, for the treatment of people with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG).

  • Here's Why Momentum Investors Will Love Sesen Bio (SESN)
    Zacks8 months ago

    Here's Why Momentum Investors Will Love Sesen Bio (SESN)

    Does Sesen Bio (SESN) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Sesen Bio (SESN) Continue to Surge Higher?
    Zacks8 months ago

    Sesen Bio (SESN) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Sesen Bio, Inc. (SESN).

  • ACCESSWIRE8 months ago

    3 Cancer Treatment Stocks that Moved Higher in August

    Furthermore, many of the smaller biotechnology stocks have been garnering more interest for novel therapies and even more interest from some of their larger cohorts. A multi-million dollar strategic investment into one of the biotech companies this week has continued to emphasize the focus on the potential that smaller cap biotech companies hold. GT Biopharma (GTBP) for example is generating novel immuno-oncology biopharmaceutical drugs targeting cancers.

  • Business Wire8 months ago

    Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates

    FDA Grants Fast Track Designation for Vicinium in NMIBC

  • Business Wire8 months ago

    Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer

    Sesen Bio, Inc. (SESN), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Vicinium™ for the treatment of BCG-unresponsive high-grade non-muscle invasive bladder cancer (NMIBC). Vicinium, Sesen Bio’s lead product candidate, is currently being evaluated in a Phase 3 registration trial, the VISTA Trial, for the treatment of patients with high-grade NMIBC who have previously received two courses of bacillus Calmette-Guérin (BCG) and whose disease is now BCG-unresponsive.

  • Business Wire9 months ago

    Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month VISTA Trial Data and Regulatory Submission in 2019

    Thomas Cannell, DVM has been appointed chief executive officer and a member of the board of directors, bringing with him a wealth of leadership experience in building and overseeing strategic operations and global pharmaceutical commercialization for life science companies. Stephen Hurly left his employment with Sesen Bio effective August 7, 2018. “Over the last two years, Sesen Bio has undergone a unique evolution as a company.

  • Business Wire9 months ago

    Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference

    Sesen Bio, Inc. , a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that company management will present a corporate overview at the Canaccord Genuity 38th Annual Growth Conference on Thursday, Aug.

  • ACCESSWIRE9 months ago

    Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks

    Stock Research Monitor: OGEN, ONCE, and SBOT LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration . Ahead of today's trading ...